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Abstract
Background: A novel tyrosine kinase receptor EphA2 is expressed at high levels in advanced and
metastatic cancers. We examined whether vaccinations with synthetic mouse EphA2 (mEphA2)-derived
peptides that serve as T cell epitopes could induce protective and therapeutic anti-tumor immunity.
Methods: C57BL/6 mice received subcutaneous (s.c.) vaccinations with bone marrow-derived dendritic
cells (DCs) pulsed with synthetic peptides recognized by CD8+ (mEphA2671–679, mEphA2682–689) and
CD4+ (mEphA230–44) T cells. Splenocytes (SPCs) were harvested from primed mice to assess the
induction of cytotoxic T lymphocyte (CTL) responses against syngeneic glioma, sarcoma and melanoma
cell lines. The ability of these vaccines to prevent or treat tumor (s.c. injected MCA205 sarcoma or B16
melanoma; i.v. injected B16-BL6) establishment/progression was then assessed.
Results: Immunization of C57BL/6 mice with mEphA2-derived peptides induced specific CTL responses
in SPCs. Vaccination with mEPhA2 peptides, but not control ovalbumin (OVA) peptides, prevented the
establishment or prevented the growth of EphA2+ or EphA2-negative syngeneic tumors in both s.c. and
lung metastasis models.
Conclusions: These data indicate that mEphA2 can serve as an attractive target against which to direct
anti-tumor immunity. The ability of mEphA2 vaccines to impact EphA2-negative tumors such as the B16
melanoma may suggest that such beneficial immunity may be directed against alternative EphA2+ target
cells, such as the tumor-associated vascular endothelial cells.
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Background
EphA2 is a member of Eph family of receptor tyrosine
kinases comprised of two major classes (EphA and EphB),
which are distinguished by their specificities for ligand
(ephrin-A and ephrin-B, respectively [1-3]). Recent
reports suggest that EphA2 is frequently overexpressed
and often functionally dysregulated in advanced cancers,
where it contributes to multiple aspects of malignant
character. These changes in EphA2 have been observed in
a wide array of solid tumors, including melanoma [4,5]
and prostate [6], breast [7] and lung [8] carcinomas.
Indeed, the highest degree of EphA2 expression among
tumors is most commonly observed in metastatic lesions
[6,9].
These data suggest that EphA2 may serve as an attractive
target for cancer vaccines. In this regard, we have identi-
fied five human leukocyte antigen (HLA)-A2 binding and
three HLA-DR4-binding peptides derived from EphA2
that are capable of inducing specific, tumor-reactive CD8+
or CD4+ T-cell responses, respectively [10]. A more recent
report has identified two additional HLA-A2 restricted T-
cell epitopes encoded by EphA2 [11].
These observations and findings support our rationale for
near future implementation of EphA2-targeted vaccine
clinical trials. For pre-clinical evaluation of EphA2-tar-
geted vaccines, however, there is little information on
immune responses against EphA2 in mouse models.
Therefore, we hypothesized that identification of mouse
T-cell epitopes in mEphA2 would allow us to determine
the effect of EphA2-targeted vaccinations in mice bearing
tumors. In this study, we examined whether novel T-cell
epitope peptides identified in the mEphA2 protein
sequence could elicit protective and therapeutic anti-
tumor immune responses in murine models. Our results
indicate that DC-based vaccines incorporating these pep-
tides elicit effective CTL responses that can inhibit the
growth both EphA2+ and EphA2-deficient tumors.
Materials and methods
Animals
Female 6–8-week-old C57BL/6 mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). Animals were
handled under aseptic conditions in microisolator cages
within the Central Animal Facility at the University of
Pittsburgh per an Institutional Animal Care and Use Com-
mittee-approved protocol, and in accordance with recom-
mendations for the proper care and use of laboratory
animals.
Cell Lines and Culture
Glioma cell lines KR129, KR130, KR233 and KR158D
were derived from spontaneously arising gliomas in F1
between B6 × CBA (KR129), B6 × SJL (KR130), and
C57BL/6 (KR233 and KR158D)-background NPcis mice
that express mutations in two tumor-suppressor genes,
Nf1 and Trp53 [12]. B16 melanoma, NPcis-derived gli-
oma cells, GL261 glioma and MCA205 sarcoma (H-2b)
cell lines were cultured in complete medium (CM) [RPMI
1640 supplemented with 10% heat-inactivated fetal
bovine serum, 100 units/ml penicillin, 100 µg/ml strepto-
mycin, and 10 mM L-glutamine (all reagents from Life
Technologies, Inc., Grand Island, NY)] in a humidified
incubator in 5% CO2 at 37°C.
Generation of DCs in Vitro from Bone Marrow
The procedure used to generate DCs has been previously
described [13]. Briefly, C57BL/6 bone marrow cells were
cultured in CM supplemented with 1000 units/ml recom-
binant mouse granulocyte/macrophage colony-
stimulating factor and recombinant mouse interleukin-4
(Schering-Plough, Kenilworth, NJ) at 37°C in a humidi-
fied, 5% CO2 incubator for 7 days. DCs were then isolated
at the interface of 14.5% (w/v) metrizamide (Sigma, St.
Louis, MO) in CM discontinuous gradients by centrifuga-
tion. DCs typically represented >90% of the harvested
population of cells based on morphology and expression
of the CD11b, CD11c, CD40, CD54, CD80, CD86, and
class I and class II MHC antigens as assessed using flow
cytometry (data not shown).
Peptides and immunization
The protein sequences of mEphA2 was obtained from
GenBank and analyzed for H-2Kb-, H-2Db-, and I-Ab-
binding binding motifs using BIMAS, and a proteosomal
cleavage site prediction system [14], respectively. Peptide
sequences that were given high binding scores and pre-
dicted proteosomal cleavage sites at the ends of the
sequences were chosen [15]. The H-2Db-binding
mEphA2671–679  (FSHHNIIRL), H-2Kb-binding
mEphA2682–689  (VVSKYKPM), and I-Ab-binding
mEphA230–44 (LLDFAAMKGELGWLT) epitopes were syn-
thesized using an automated solid-phase peptide synthe-
sizer (Applied Biosystems, Foster City, CA) by the protein
synthesis facility at the University of Pittsburgh Cancer
Institute, purified (to greater than 95%) by reverse phase
HPLC, and characterized for amino acid sequences by
mass spectrometry.
Day 7 DCs were pulsed with 10 µM each of the indicated
peptides for 4 hours at 37°C, as previously described [13].
Cells were then washed twice with Hank's balanced salt
solution (HBSS), with animals receiving injections of the
indicated numbers of peptide-pulsed DCs in 0.1 ml HBSS
s.c.
Tumor challenge
In the s.c. model, animals were injected with the indicated
numbers of tumor cells in the right flank. Anti-tumorJournal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
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responses were assessed based on comparative longitudi-
nal measurements of tumor area. In the lung metastasis
model, animals were injected i.v. with 2 × 105 B16-BL6
tumor cells on day 0, and they subsequently received s.c.
vaccinations of peptide-loaded DCs on days 3, 10 and 17.
Animals were sacrificed on day 28 post-tumor injection
and analyzed for the assessment of pulmonary metastases
by enumerating the number of surface tumor-nodules.
Western Blotting
Protein lysates isolated from normal mouse brain, spleen,
liver, lung, heart, skeletal muscle, and mouse tumor lines
were separated by SDS-PAGE, blotted onto nitrocellulose
and analyzed for expression of mEphA2 using EphA2
monoclonal antibody (C-20 Ab; Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). Blots were imaged on Kodak X-
Omat Blue XB-1 film (NEN Life Science Products, Boston,
MA) after using horseradish peroxidase (HRP)-conjugated
goat anti-rabbit Ig (Biorad, Hercules, CA) and the Western
Lighting™ chemiluminescence detection kit (Perkin
Elmer, Boston, MA).
CTL activity assay
Single cell suspensions of SPCs were cultured at 2 × 106
cells/ml with 2 µg/ml mEphA2671–679 or mEphA2682–689 in
presence of 10 U/ml human IL-2 (Chiron, Emeryville,
CA), 50 µM 2-mercaptoethanol (Sigma), and 50 µM NG
mono-methyl-L-arginine (Cyclopss, Salt Lake City, UT) in
24 wells plates (Corning, Corning, NY) for 5 days. Specific
CTL activity was determined in 4 h 51Cr release assays
against the indicated target cells, as previously described
[16].
Matrigel plug assay
Eight-week-old mice were injected s.c. twice (days -14 and
-7) with DCs loaded with either EphA2-derived peptides
(EphA2 671–679/30–44) or OVA-derived peptides (OVA 257–
264/265–280). Each animal then received 400 µl of Matrigel
(BD Biosciences) supplemented with 400 ng/ml vascular
endothelial growth factor (VEGF) in the dorsal area [17].
The animals were sacrificed 10 days later, then the plugs
were removed and photographed.
Statistical analysis
Comparative numbers of lung metastasis, growth of s.c.
tumors and T cell responses were compared by Student's t
test for two samples with unequal variances. Statistical sig-
nificance was determined at p value <0.05.
Results
Expression of mEphA2 in murine tumor cells
We evaluated the expression of mEphA2 in H-2b-syn-
geneic murine tumor cell lines and normal organs from
C57BL/6 mice by Western Blotting (Figure 1). MCA205
sarcoma, the NPcis mice-derived spontaneously devel-
oped glioma cell lines KR129, KR130, KR233 and
KR158D (Figure 1A), as well as, the GL261 glioma (Figure
1B) expressed detectable but variable levels of mEphA2
protein. In marked contrast, none of melanoma lines
tested, including B16 melanoma and its more metastatic
sub-clones B16V1 and B16BL6, expressed detectable lev-
els of mEphA2 (Figure 1A). The control β-actin staining
on the same blots demonstrated that equal amount of
protein was loaded in each lane. With regard to the nor-
mal organs examined, moderate levels of mEphA2 expres-
sion were identified in the spleen, liver and lung, whereas
no detectable expression was observed in brain, heart and
skeletal muscle (Figure 1B).
Vaccination of mice with synthetic mEphA2 T cell epitopes 
promotes specific CTL responses
We have previously characterized the immunogenicity of
the H-2Db-binding mEphA2671–679, H-2Kb-binding
mEphA2682–689, and I-Ab-binding mEphA230–44 epitopes
based on delayed-type hypersensitivity responses in B6
mice (Storkus et al., unpublished results). We immunized
syngeneic C57BL/6 mice twice s.c. with syngenic DCs
loaded with the Kb-binding and the I-Ab-binding epitopes,
or DCs loaded with the Db-binding and the I-Ab-binding
epitopes on a weekly basis. Control animals received DCs
loaded with the cancer-irrelevant Kb-binding OVA257–264
and the I-Ab-binding OVA265–280 epitopes [18]. One week
after the secondary immunization, the animals were sacri-
ficed, and SPCs were harvested. The SPCs were then stim-
ulated in vitro with the MHC class I peptide that was used
for in vivo immunization, in the presence of 10 U/ml hIL-
2, for 7 days. SPCs from control animals immunized with
OVA peptides were stimulated in vitro with the
mEphA2671–79 to provide an index for a control, "primary"
level of specific CTL induction. CTL activity against
mEphA2-expressing, and H-2b-syngeneic MCA205 sar-
coma, GL261 glioma and KR158D glioma cells were
assessed by standard 51Cr-release assays (Figure 2). All
three mEphA2+ cell lines demonstrated susceptibility to
CTLs generated by the immunizations with Kb- or Db-
binding mEphA2 derived epitopes. With 20 h – incuba-
tion time, the percent lysis by EphA2-induced CTLs
increased remarkably in comparison to 4 h-incubation
regimen, whereas the lysis by OVA-induced CTLs do not,
suggesting that the specific lysis can be more appreciated
with the prolonged incubation time (up to 20 h) for the
CTLs raised against EphA2-epitopes. B16 melanoma and
YAC cells, which were used as negative control target cells,
displayed constantly less than 10% of specific lyses in all
groups (data not shown). These data support the conclu-
sion that these mEphA2-derived peptides may serve as
effective  in vivo immunogens for anti-tumor T cell
activation.Journal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
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mEphA2 peptide-pulsed DC-based vaccines effectively 
protect/treat s.c MCA205 sarcoma and B16 melanoma
We evaluated the efficacy of protective and therapeutic
immunizations with mEphA2-derived peptides in s.c.
tumor models. These included the mEphA2-positive
MCA205 sarcoma and the mEphA2-negative B16
melanoma models. First, animals bearing established s.c.
MCA205 tumors received therapeutic vaccinations with
mEphA2-derived CTL (H-2Kb or H-Db presented) + Th
epitope peptides on days 3 and 10 following tumor inoc-
ulation (5 animals/group). Control animals received DCs
loaded with the OVA-derived CTL + Th epitopes. As dis-
played in Figure 3A, vaccination with either combination
of mEphA2-derived CTL (H-2Kb or H-Db presented) + Th
epitope peptides significantly inhibited the growth of
tumors in comparison to control vaccinations with irrele-
vant (OVA)-derived T cell epitopes.
We next examined whether vaccination with mEphA2-
derived peptides could induce anti-tumor effects against
Expression of EphA2 in murine tumor cell lines and tumor/normal tissues Figure 1
Expression of EphA2 in murine tumor cell lines and tumor/normal tissues. (A) Aliquots of protein lysates (10 µg/
lane) were analyzed by Western Blotting for expression of mEphA2 protein using a specific monoclonal antibody (C-20 Ab; 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Lysate samples were obtained from mouse tumor lines including the B16, 
B16V1 and B16BL6 melanomas and the KR129, KR130, KR233 and KR158D glioma cell lines derived from spontaneously 
developed glioma tissues in NPcis mice. Control β-actin labeling demonstrated equal amount of protein loading in each lane. 
(B) Protein lysates isolated from normal mouse brain, spleen, liver, lung, heart, skeletal muscle, and the G261 glioma and MCA 
205 sarcoma cell lines were separated by SDS-PAGE, blotted onto nitrocellulose and analyzed for expression of mEphA2 using 
C-20 anti-EphA2 monoclonal antibody.Journal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
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mEphA2-negative tumors, expecting that this would not
be the case. Since s.c. B16 melanomas grow aggressively,
we employed a pre-immunization model to assess the
anti-tumor response. Syngeneic C57BL/6 mice were pre-
immunized with either mEphA2671–679, mEphA2682–679,
or mEphA230–44 peptides on days -14 and -7 before s.c.
injection with 5 × 104 B16 cells on day 0 (5 animals/
group). The control group received irrelevant OVA257–264
instead of mEphA2-derived peptides. Tumor size and the
number of animals that had measurable tumors are
assessed on day 21 (Figure 3B). All control animals receiv-
ing OVA-immunization developed large tumors, whereas,
surprisingly, 3 of 5 animals in each of mEphA2-derived
peptide-treated groups rejected the tumor growth. Indeed,
the average tumor size in each of mEphA2-immunized
groups was significantly smaller than the control groups
(P < 0.01). As B16 melanoma cells did not express
mEphA2 protein in vitro (Figure 1A), these data suggest
that vaccination with mEphA2-derived peptides may
induce  in vivo CTL activity not only directly against
Immunizations with mEphA2-derived peptides elicit anti-tumor CTLs Figure 2
Immunizations with mEphA2-derived peptides elicit anti-tumor CTLs. C57BL/6 mice received two cycles of s.c. 
immunization with 5 × 105 DCs loaded with mEphA2-derived peptides or control OVA-derived peptides. One week after the 
second immunization, the animals were sacrificed, and SPCs were re-stimulated in vitro with the indicated peptides in the pres-
ence of 20 IU/ml hIL-2 for 7 days. Standard 4-hr (upper panel) and 20-hr (lower panel) 51Cr-release assays were used to assess 
cytotoxicity of the responder SPCs against the EphA2+ MCA205, GL261 and KR158D tumor cell lines. Each value represents 
the average of triplicate determinations for each group. YAC cells were evaluated as non-specific target cells, while EphA2-neg-
ative B16 melanoma cells were examined as negative control target cells in all groups, with the lysis of each of these targets 
constantly less than 10% (data not shown).Journal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
Page 6 of 9
(page number not for citation purposes)
mEphA2 expressed in tumors, but also against mEphA2
expressed by other critical components of tumor-struc-
ture, such as tumor vascular endothelial cells. With regard
to EphA2 expression in vivo, we attempted immunohisto-
chemistry on s.c. B16 tumors to directly validate EphA2
expression. Although deposition of endogenous melanin
in B16 tissues posed interference for the substrate-devel-
opment, we did not observe EphA2-specific staining in s.c.
B16 tumor tissues (data not shown).
EphA2 peptide-pulsed DC-based vaccines protect against/
treat B16-BL6 lung metastasis
We next evaluated a lung metastasis model using B16-BL6
melanoma cell line. Syngeneic C57BL/6 mice received 2 ×
105 B16-BL6 melanoma cells via tail vein injection. The
animals subsequently received s.c. immunizations with 1
× 106 DCs loaded with mEphA2 CTL (H-2Kb or H-Db pre-
sented) + Th on days 3, 10 and 17 (5 animals/group).
Control animals received DCs loaded with the OVA CTL +
Th epitopes. On day 28, the animals were sacrificed, and
the lungs harvested from each animal. The number of sur-
face pulmonary metastases and lung weight were meas-
ured and compared between the groups. As demonstrated
in Figure 4A and 4B, both of mEphA2-immunization reg-
imens resulted in remarkable suppression of B16-BL6
lung metastases in comparison to the OVA-immunized
control group in this early-stage treatment model.
VEGF has been implicated to be a major mediator of
tumor-angiogenesis [19,20], and EphA2-blockade has
been shown to inhibit VEGF-induced angiogenesis [21].
To examine whether immunizations with mEphA2-
derived peptides inhibit VEGF-induced angiogenesis,
Matrigel plugs containing VEGF were implanted in pre-
immunized mice and recovered 10 days later. Macro-
scopic analysis revealed that the plugs from mice pre-
immunized with mEphA2-derived peptides were much
paler than those from control mice (Figure 4C). These
results suggest that vaccinations with mEphA2-derived T
cell epitopes may induce potent anti-tumor responses in
Immunizations with DCs loaded with Eph-A2 derived peptides inhibit the growth of both EphA2-positive and EphA2-negative  tumors Figure 3
Immunizations with DCs loaded with Eph-A2 derived peptides inhibit the growth of both EphA2-positive and 
EphA2-negative tumors. (A) C57BL/6 mice received 1 × 105 MCA205 cells s.c. on day 0. These animals were then immu-
nized with 1 × 106 DCs loaded with the indicated peptides on days 3, 10. Tumor growth was monitored for 28 days following 
the tumor inoculation (N = 5/group). P < 0.05 for both mEphA2671–679/30–44 and mEphA2682–689/30–44 treatments in comparison 
to OVA control for the tumor based on a two-tailed Student-t test (*). (B) C57BL/6 mice received s.c. pre-immunizations with 
1 × 106 DCs loaded with either mEphA2671–679, mEphA2682–689, mEphA230–44 or control OVA257–264 on days -14 and -7 (N = 5 /
group), followed by s.c. challenge with 5 × 104 B16 melanoma cells on day 0. On day 14, the size of tumors and the number of 
animals that had measurable tumors were assessed. P < 0.01 for EphA2671–679, EphA2682–689 and EphA230–44 treatments in com-
parison to OVA257–264 treated group (*).Journal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
Page 7 of 9
(page number not for citation purposes)
mEphA2-deficient tumor models through inhibition of
tumor angiogenesis.
Discussion
In this report, we have demonstrated that mEphA2-
derived peptide epitopes can elicit specific CTL responses
and anti-tumor response in vivo. Of major note, the anti-
tumor response was not restricted to mEphA2-postive
models, but was also observed in the case of both s.c. and
metastatic B16 melanoma models.
While the melanoma cell lines were negative for EphA2
expression in vitro as assessed by Western Blotting, it was
conceivable that they had become EphA2+ after in vivo
injection, which could more easily explain the efficacy of
the mEphA2 peptide-based vaccinations. However, we
Inhibition of B16-BL6 lung metastasis and VEGF-induced angiogenesis by s.c. immunizations with DCs loaded with EphA2- derived peptides Figure 4
Inhibition of B16-BL6 lung metastasis and VEGF-induced angiogenesis by s.c. immunizations with DCs loaded 
with EphA2-derived peptides. (A and B), C57BL/6 mice received i.v. injections of 2 × 105 B16-BL6 cells followed by s.c. 
immunizations with 1 × 106 DCs loaded with the indicated peptides on days 3, 10 and 17 (N = 4/group). The animals were sac-
rificed on day 28, with representative macroscopic pictures of the harvested lungs from each group (A) and the numbers of 
pulmonary surface metastases counted (B) P < 0.001 for both mEphA2671–679/30–44 (*) and mEphA2682–689/30–44 (**) treatments in 
comparison to OVA control for the number of metastasis based on two-tailed Student-t test. (C), mEphA2-targeted immuniza-
tions inhibited the vascular formation in the Matrigel plug assay. Syngeneic mice pre-immunized with control OVA- (left) or 
EphA2- (right) peptides were injected s.c. with Matrigel containing VEGF. After 10 days, the plugs were removed and photo-
graphed. The picture shows representative VEGF-containing plugs excised from total 5 mice/group.Journal of Translational Medicine 2004, 2:40 http://www.translational-medicine.com/content/2/1/40
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were unable to detect mEphA2 expression even in the in
vivo grown B16 tumors (data not shown), suggesting that
the T-cell immunity against mEphA2-derived epitopes
suppress the in vivo tumor-growth not only through the
direct anti-tumor cell mechanisms but also through indi-
rect mechanisms, such as inhibition of tumor-angiogen-
esis.
The Eph kinases and ephrins play a crucial role in vascular
development during embryogenesis and tumor formation
[1]. In two independent tumor types, the RIP-Tag trans-
genic model of angiogenesis-dependent pancreatic islet
cell carcinoma and the 4T1 metastatic mammary adeno-
carcinoma, Ephrin-A1 ligand is expressed in both tumor
and endothelial cells, and EphA2 receptor was localized
primarily in tumor-associated vascular endothelial cells
[3]. Soluble EphA2-Fc or EphA3-Fc receptors inhibit ang-
iogenesis and tumor formation in multiple models [3,22].
Further molecular analyses revealed that the EphA-eph-
rinA interaction is necessary for VEGF-induced angiogen-
esis [21,22]. These published observations suggest that
immunological targeting of EphA2 may also inhibit
tumor growth by suppression of tumor-neoangiogenesis.
Immunization against angiogenic-associated antigens
selectively expressed on tumor vasculature may provide
for a novel strategy to block tumor growth. The feasibility
of this approach has been borne out in reports demon-
strating that the protein or DNA encoding angiogenic
molecules, such as VEGF-R2, can be used as a vaccine to
generate effective CTL and antibody responses against
tumor vessels, thereby limiting tumor growth and metas-
tasis [19,20]. In this regard, our results with Matrigel
assays suggest that immunization of C57BL/6 mice with
mEphA2-derived peptides may inhibit VEGF-induced
angiogenesis. We are currently confirming these
observations with quantitative analyses of vessel forma-
tions in the Matrigel plugs.
As expected, based on our Western Blotting, several nor-
mal organs examined expressed EphA2 including the
spleen, liver and lung. This could provide concern for the
potential clinical translation of EphA2-based vaccines,
given concerns for autoimmune pathology that might
occur in these anatomic sites. However, despite the effec-
tive induction of antigen-specific CTLs that are capable of
mediating DTH-type reactivity (unpublished data) and
anti-tumor responses in situ, our careful observation of
EphA2-vaccinated animals at autopsy did not reveal any
evidence for tissue infiltration by inflammatory leuko-
cytes or the destruction of EphA2+ tissues.
In our assessment of CTL and anti-tumor response, in
most cases, we employed both MHC class I and II associ-
ated peptides in our treatment regimens based on our pre-
vious study demonstrating that the combination of MHC
class I and II-restricted OVA-immuno-epitopes induced
higher levels of anti-tumor efficacy than MHC class I-
restricted OVA-epitopes solely [18]. With regard to the
immunogenicity of each mEphA2-derived peptide, our
data with preimmunizations against s.c. B16 challenge
indicated that each of mEphA2 671–679, mEphA2 682–689
and mEphA2 30–44 could induce anti-tumor response. It
was noteworthy that mEphA2 30–44, which was found to
bind I-Ab  and induce DTH and specific CD4+ T cell
responses, also suppressed the growth of s.c. (MHC class
II-deficient) B16 melanomas as a single agent. This may
suggest that neovessels in the B16 microenvironment are
MHC class II+ either constitutively or under inflammatory
conditions under which IFN-γ is elaborated, that B16
melanomas become class II+ after in vivo transfer or upon
provision of IFN-γ in situ, or that the mEphA2 30–44 Th
peptide also contains an embedded CTL epitope. We are
currently assessing each of these possibilities.
It is also intriguing to determine whether there is a corre-
lation between expression levels of mEphA2 in the target
cells and their susceptibility to CTLs raised against EphA2-
derived peptides. Our preliminary data indicated EphA2
expression levels did not simply correlate with the CTL
susceptibility, suggesting other factors, such as MHC class
I expression and intracellular anti-apoptotic proteins, may
contribute in the CTL-mediated cytotoxicity (data not
shown). To address this issue, our ongoing studies with
human glioma cells employ small inhibitory RNA for
EphA2 to determine whether specific inhibition of
EphA2-expression affects the CTL response.
Conclusions
Although the precise mechanisms that underlie the anti-
tumor efficacy of EphA2-based vaccines remain to be
elucidated, our results demonstrate that the mEphA2-
derived epitopes may represent important vaccine
candidates for the development of clinical trials for the
treatment of (both EphA2+ and EphA2-negative) cancers.
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